We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.25 | -6.77% | 44.75 | 44.50 | 45.00 | 46.00 | 44.60 | 44.60 | 143,492 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 169.74M | -23.15M | -0.0313 | -14.38 | 332.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/10/2018 12:17 | :O That's a big sell... Enjoy the rollercoaster! | btfd497 | |
22/10/2018 11:33 | 6 million share trade. That's nearly 1.1% of the Company. I wonder what the story behind it is. | murdo mcsponge | |
13/10/2018 12:39 | I agree with you - a very long term hold, but IMHO it's doing all the right things in a fast expanding industry and has a team that understands that industry. | murdo mcsponge | |
12/10/2018 18:22 | Been holding these for almost a year now. I should have taken some profits when it rose to 80p but i got greedy... I still have faith in the company and am wait for their next trading update so the share price can rise again. I think this is a great long term share. | btfd497 | |
03/10/2018 07:27 | Purchase of Videntis. Good move IMHO. | murdo mcsponge | |
11/9/2018 23:16 | Sea lice on salmon getting a lot of publicity recently with a feature even making it's way on to the One Show the other day. Benchmark's Clean Treat system could prove a very interesting and hopefully profitable development for the company. Worth watching the process Dibbs | dibbs | |
17/8/2018 09:44 | Jimarilo,you are totally wrong in believing that farmed salmon are full of chemicals and fat.farming of salmon has progressed significantly over the last few years and use of chemicals has largely disappeared.The use of cleaner fish ,balian wrasse and lumpfish(both now farmed rather than caught)has been very successful in reducing sea lice levels and fresh water treatments are now proving successful in both lice control and ensuring gill health.I have just returned from Norway.They produce 1.3m tonnes per annum and used I understand used only 278kg last year of antibiotics etc. On the feeding side the industry is now far more dependant on grain based feed rather than fishmeal. Overall salmon farming beats pork,beef etc handsdown as a way of producing protein. | mjcferguson | |
13/8/2018 03:58 | I won't touch farmed salmon, full of fat and chemicals Not to mention the effect on wild salmon and sea trout, this is not a sustainable business in it's current form | jimarilo | |
13/8/2018 02:47 | Should be captivity, using a very small keyboard and I've been awake a long time. | petes5 | |
13/8/2018 02:46 | Not holding these at the moment but just read an article about sea wraas. These are used on salmon farms for keeping lice under control but until now have had to be taken from the wild and populations are dropping. They are now able to breed these in cativity. This could be a major game changer in keeping lice under control but state that other methods will still be utilised. | petes5 | |
06/7/2018 10:00 | If you want to see the CEO and CFO run through the recent results and talk about company prospects , 30 min video interview here: | edmonda | |
26/6/2018 17:20 | Updated research just published on Benchmark's strategic positioning and new fair value calculation. Freely available at: | edmonda | |
22/6/2018 07:13 | Follow directors buy | nw99 | |
12/6/2018 17:21 | It's all in the RNS... just click on the link under the header above for 8th June Trading Update Don't just read a news 'story' e.g. Placing of New Ordinary Shares The JV is being funded by a placing of 34,545,455 new ordinary shares (the "Placing Shares") at a price of 55 pence per share (the "Placing Price") to raise £19m before expenses (the " Placing "). ...and there's *full* details of all EBITDA calcs for the next 3 years... The deal looks good to me, and the offering has been well received. | tinman | |
12/6/2018 17:10 | after last week's trading update, JV in Chile and associated placing: new research note out ahead of results 19 June. Freely available here: … | edmonda | |
08/6/2018 14:56 | Oh, & an XR or OO for PIs? Nah, they don't even make it clear at what price these new shares are being "valued". I'm told it is 55p.... "Placing to raise GBP19.0 million (before expenses)" - How many shares? "Acquisition of 49% interest " - minority holding.... This really puzzles me : - "adjusted EBITDA contribution: -- in the four months to 30 September 2018 of GBP1.81m" (= GBP 5.4m per annum) "-- for the first full year to 30 September 2019 of approximately GBP2.4m" (so why less than half of above?) "-- of GBP4.1m at full capacity" (getting there.......!) I used to have some of these. In no hurry to buy back in. | napoleon 14th | |
08/6/2018 14:52 | Now we know why the fall in share price Funny how the market knew, innit? I mean, far be it for me to suggest........ | napoleon 14th | |
22/5/2018 21:09 | He also knows we have the same golf handicap | lucicavi | |
22/5/2018 21:03 | Johnson 09 knows nothing | nw99 | |
21/5/2018 13:21 | 61-62 nice and tight. Shall i buy another 20 or shall i let johnson09 have them | lucicavi | |
21/5/2018 12:45 | What’s it all about? Benchmark is a highly interesting player in the booming Aquaculture industry, which ticks many ESG boxes. Through M&A, a unique platform has been built with significant exposure to the high value added, early life stages of fish. The portfolio includes a range of seed, feed and healthcare products, with prospects of double-digit sales growth on >20% EBITDA margins for 2016-18E. That said, earnings visibility is limited and we fear that the capital return profile will remain unattractive for several years. We would welcome a temporary step back from M&A and a focus on achieving revenue synergies. The shares trade at an adjusted 2017 EBITDA multiple of 12x, and our DCF analysis comes out at 95p. Backed by our SOP fair value of 73p per share, we initiate coverage with a Buy rating. | rubberbullets | |
21/5/2018 12:32 | NEW recent high now,. | rubberbullets | |
21/5/2018 11:12 | TAKE OFF TIME | rubberbullets |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions